Shennon Biotechnologies
United States · Biotech
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
Finding functional cancer-targeting therapies
Shennon combines target discovery, microfluidics-driven screening, computational therapeutic design and predictive safety assessment to develop T-cell engagers. Its TCELERATOR platform measures more than 10 million single-cell interactions in one experiment, helping identify functional candidates from human tumor biology rather than relying only on sequential binder tests.
The company is developing antibody- and T-cell-receptor-based programs for solid tumors, including small-cell lung, ovarian and liver cancers. Its platform and early pipeline are in discovery and preclinical development, with oncology drug developers and clinical collaborators as the relevant partners.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Funding | $12M | Atypical Ventures — ParticipantAV8 Ventures — ParticipantDCVC — ParticipantFoundation Capital — ParticipantFuture Ventures — ParticipantNextGen Venture Partners — ParticipantSamos Investments — ParticipantSaras Capital — Participant |